Novel therapeutic approaches for recurrent nonmuscle invasive bladder cancer

Brock E. Boehm, Robert S. Svatek

Producción científica: Review articlerevisión exhaustiva

10 Citas (Scopus)


This article summarizes strategies being investigated in patients with nonmuscle invasive bladder cancer. Progress has been made toward improving the delivery method of intravesical agents. Intravesical therapy is limited by the amount of time that the agent remains in contact with the bladder. Bladder cancer is considered to be responsive to immune therapy. Thus, many novel approaches are immune-based therapies and include cancer vaccines, use of Bacillus Calmette-Guérin (BCG) subcomponents, and checkpoint inhibitors. Finally, access to bladder mucosa via direct catheterization into the bladder via the urethra has enabled unique strategies for delivery of cancer therapy including viral- or plasmid-based gene therapy.

Idioma originalEnglish (US)
Páginas (desde-hasta)159-168
Número de páginas10
PublicaciónUrologic Clinics of North America
EstadoPublished - 2015

ASJC Scopus subject areas

  • Urology


Profundice en los temas de investigación de 'Novel therapeutic approaches for recurrent nonmuscle invasive bladder cancer'. En conjunto forman una huella única.

Citar esto